Endothelial function and dysfunction: Impact of sodium-glucose cotransporter 2 inhibitors

Pharmacol Ther. 2021 Aug:224:107832. doi: 10.1016/j.pharmthera.2021.107832. Epub 2021 Mar 1.

Abstract

Diabetes mellitus is associated with endothelial dysfunction that leads to cardiovascular complications. Sodium-glucose cotransporter 2 (SGLT2) inhibitors demonstrated efficacy in glycemic control in type 2 diabetes patients with positive cardiovascular outcome. Recent research revealed a link between SGLT2 inhibition and improved macro- and microvascular endothelial functions. Mechanisms underlying this phenomenon could be due to the role of SLGT2 in the regulation of endothelial physiology. In this review, current knowledge and hypothesis on the link between SGLT2 and endothelial function were critically appraised and the impact of SGLT2 inhibitors on endothelial dysfunction in pre-clinical and clinical studies was discussed.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Diabetes Mellitus, Type 2 / drug therapy
  • Diabetes Mellitus, Type 2 / physiopathology
  • Endothelium* / physiology
  • Endothelium* / physiopathology
  • Humans
  • Sodium-Glucose Transporter 2 Inhibitors* / pharmacology

Substances

  • Sodium-Glucose Transporter 2 Inhibitors